|
Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data. |
|
|
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Eisai; Eisai; G1 Therapeutics; Lilly; MedImmune; Novartis; Sandoz; Seagen; Takeda |
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst) |
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst) |
|
|
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (I) |
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Genmab (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Tarveda Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Speakers' Bureau - Bristol-Myers Squibb |
Research Funding - Abbvie (I); Bristol-Myers Squibb (Inst); Celldex (Inst); Dynavax Technologies (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst); Reata Pharmaceuticals (Inst) |
|
|
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Celgene; Cerulean Pharma; EUSA Pharma; Janssen-Cilag; Nanobiotix; Novartis; Pierre Fabre; PsiOxus Therapeutics; Seagen |
Speakers' Bureau - Novartis |
Research Funding - Abbvie; Amcure; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CytomX Therapeutics; H3 Biomedicine; Incyte; Janssen Oncology; Kura Oncology; Lilly; Loxo; Macrogenics; Menarini; Merck; Merck Serono; Merus; Millennium; Nanobiotix; Nektar; Novartis; Pfizer; PharmaMar; Principa Biopharma; PsiOxus Therapeutics; Puma Biotechnology; RigonTEC; Roche/Genentech; Sanofi; Synthon; Taiho Pharmaceutical; Tesaro |
Travel, Accommodations, Expenses - Celgene; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; PharmaMar; Roche; Tesaro |
Speakers' Bureau - AstraZeneca; PharmaMar; Roche; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche; Tesaro |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Abbvie |
Travel, Accommodations, Expenses - Abbvie |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
Employment - Novartis; Regeneron |
Stock and Other Ownership Interests - Novartis; Regeneron |
|
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene; Merck; Regeneron |
|
|
|
|
Stock and Other Ownership Interests - Regeneron |
Travel, Accommodations, Expenses - Regeneron |
|
|
Employment - Regeneron; Regeneron (I) |
Stock and Other Ownership Interests - Regeneron; Regeneron (I) |
Consulting or Advisory Role - Egenix |
Research Funding - AstraZeneca/MedImmune; Novartis; Regeneron |
Patents, Royalties, Other Intellectual Property - Regeneron (I) |
|
|
Consulting or Advisory Role - Celgene; Endocyte |